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Recent advances in our understanding of the biology of muscle have led to new interest
in the pharmacological treatment of muscle wasting. Loss of muscle mass and increased
intramuscular fibrosis occur in both sarcopenia and muscular dystrophy. Several regulators
(mammalian target of rapamycin, serum response factor, atrogin-1, myostatin, etc.) seem
to modulate protein synthesis and degradation or transcription of muscle-specific genes
during both sarcopenia and muscular dystrophy. This review provides an overview of the
adaptive changes in several regulators of muscle mass in both sarcopenia and muscular
dystrophy.
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INTRODUCTION
In humans, skeletal muscle is the most abundant tissue in the body,
comprising 40–50% of body mass and playing vital roles in loco-
motion, heat production during periods of cold stress, and overall
metabolism. Skeletal muscle is composed of bundles of muscle
fibers called fascicles. The cell membrane surrounding the muscle
cell is the sarcolemma, beneath which lies the sarcoplasm, which
contains the cellular proteins, organelles, and myofibrils: the titin
actin filament and the thicker myosin filament. The arrangement
of these protein filaments gives skeletal muscle its striated appear-
ance. Skeletal muscle is capable of remarkable adaptations in
response to altered activity. These adjustments to mechanical and
metabolic demands elicit marked modifications of gene expression
that could lead to gain (hypertrophy) or loss (atrophy) of mus-
cle mass. Whereas, endurance training leads to minor changes in
skeletal muscle mass, strength training induces marked hypertro-
phy of exercising muscles. Resistance training [full squat, leg press,
and leg-extension, three sets to failure of 6–8 RM (~80–85% of the
1 RM, Monday) and 10–12 RM (~70–75% of the 1 RM, Friday),
18 weeks] for young sedentary subjects (women, 21.4± 1.4-year
old) elicited a 10–30% increase in fiber cross-sectional area of the
vastus lateralis muscle (Staron et al., 1991).
Loss of muscle is a serious consequence of many chronic dis-
eases and of aging itself because it leads to weakness, loss of
independence, and increased risk of death. Unfortunately, the
field suffers from having more definitions than therapies; mus-
cle wasting is an inevitable part of aging, where it is known as
sarcopenia (Rosenberg, 1989). Muscle loss is also common in mus-
cular dystrophy, in which markedly loss of various membranous
structural proteins occurs around muscle fibers (Vainzof et al.,
2008). Intriguingly, sarcopenia and muscular dystrophy possess
similar characteristics, including the accumulation of fibrosis, a
wide-range fiber size distribution, and central nuclei (Sakuma
et al., 2008; Vainzof et al., 2008; Berger and Doherty, 2010; Hepple,
2012).
In hypertrophied muscle, increasing protein synthesis and
decreasing protein degradation are also important events.
Phosphatidylinositol-3-kinase (PI3-K)/Akt/mammalian target of
rapamycin (mTOR) signaling has been shown to be crucial to
protein synthesis (Glass, 2010; Sakuma and Yamaguchi, 2012b).
Mechanical stretching in vivo and in vitro activates serum response
factor (SRF)-dependent signaling in skeletal muscle (Gauthier-
Rouviére et al., 1996; Sakuma and Yamaguchi, 2012a). In contrast,
negative regulators are proposed to induce muscle atrophy by
inhibiting protein synthesis and enhancing protein degradation
in skeletal muscle. For example, the ubiquitin–proteasome system
(UPS) is thought to be a major contributor for degrading many
structural proteins (Cao et al., 2005). However, the autophagy–
lysosome system has been largely ignored despite evidence that
lysosomal degradation contributes to protein breakdown in atro-
phying muscles (Furuno et al., 1990). Sandri (2010, 2011) has
shown that the autophagy–lysosome and UPS are coordinately
regulated during muscle wasting. On the other hand, myostatin is a
potent inhibitor of muscle growth and is considered as a therapeu-
tic target for muscle wasting including cachexia and sarcopenia,
muscular dystrophy, and amyotrophic lateral sclerosis (Sakuma
and Yamaguchi, 2011b).
Several positive and negative regulators (mTOR, SRF, atrogin-
1, p62, and myostatin) have been proposed to enhance protein
degradation or transcription of muscle-specific genes during both
sarcopenia and muscular dystrophy. However, the adaptations of
these important mediators were not necessarily similar in these
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two conditions. Muscle ring finger 1 (MuRF-1), an E3 ubiquitin
ligase, is activated in many different types of muscular dystrophy
(Saenz et al., 2008; Fanin et al., 2013, 2014), but many mediators
of UPS do not change during sarcopenia (Sakuma et al., 2014).
Several studies have indicated similar dysfunctions of autophagic
signaling during sarcopenia and muscular dystrophy (De Palma
et al., 2012; Sakuma et al., 2014). In addition, skeletal muscle in
both conditions exhibits down-regulation of SRF (Sakuma et al.,
2004, 2008) and appears to show the activation of myostatin-
dependent signaling (Sakuma et al., 2004; McKay et al., 2012). In
contrast, the adaptation of mTOR-dependent signaling seems to
differ between sarcopenia and muscular dystrophy to some extent
(De Palma et al., 2012; Sakuma et al., 2014). To build on these pre-
vious findings, more descriptive and comprehensive comparison
of positive and negative muscle regulators between sarcopenia and
muscular dystrophy is needed.
Therefore, in this review, we concentrate on specific alter-
ations discussed in the recent literature that are present in the
skeletal muscle in both muscle wasting disorders. In addition, we
focus on the adaptive changes in positive and negative regulators
(mTOR, UPS, autophagy, etc.) of muscle mass. If we can under-
stand more concretely and definitively the mechanisms underlying
sarcopenia and muscular dystrophy, more effective applications
(nutritional and/or pharmacological) for skeletal muscle wasting
may be conducted in the near future.
CHARACTERISTICS OF SARCOPENIA AND MUSCULAR
DYSTROPHY
SARCOPENIA
Aging is associated with a progressive decline of muscle mass,
quality, and strength, a condition known as sarcopenia (Candow
and Chilibeck, 2005). Although this term is applied clinically to
denote loss of muscle mass, it is often used to describe both
a set of cellular processes (denervation, mitochondrial dysfunc-
tion, inflammation, and hormonal changes) and a set of outcomes
such as decreased muscle strength, mobility, and function (Melton
et al., 2000), a greater risk of falls, and reduced energy needs. von
Haehling et al. (2010) have estimated its prevalence at 5–13%
for elderly people aged 60–70 years and 11–50% for those aged
80 years or above. Lean muscle mass generally contributes up to
~50% of total body weight in young adults, but declines with aging
to 25% at 75–80 years of age (Short et al., 2004). The loss of mus-
cle mass is most notable in the lower limb muscle groups, with
the cross-sectional area of the vastus lateralis being reduced by as
much as 40% between the ages of 20 and 80 years (Lexell, 1995). At
the muscle fiber level, sarcopenia is characterized by specific type
II muscle fiber atrophy, fiber necrosis, and fiber type grouping
(Lexell, 1995).
Several possible mechanisms for age-related muscle atrophy
have been described.
In a recent review by Demontis et al. (2013a) provides in-
depth comparison of sarcopenia in Drosophila and mammals.
Both muscles include very similar age-related changes such
as increased mitochondrial dysfunction, decreased function of
autophagy/lysosome system, increased apoptosis, and protective
role of dietary restriction. In contrast, aged Drosophila and
mammalian muscles exhibit several differential characteristics
(endocrine changes, decreased regenerative capacity via satellite
cells, defects in Ca2+ homeostasis, and increased fiber atrophy).
Age-related muscle loss is a result of reductions in the size and
number of muscle fibers, possibly due to a multi-factorial process
that involves physical activity, nutritional intake, metabolic home-
ostasis, oxidative stress, hormonal changes, and lifespan (Baum-
gartner et al., 1999; Roubenoff and Hughes, 2000; Demontis
et al., 2013b). The specific contribution of each of these factors
is unknown, but there is emerging evidence using rodent muscle
that the distribution of several positive regulators (Akt and SRF)
of muscle hypertrophy with age is an important feature in the pro-
gression of sarcopenia (Sakuma andYamaguchi,2010,2011a).Very
intriguingly, more recent studies indicated an apparent functional
defect in autophagy- and myostatin-dependent signaling in both
mice and human sarcopenic muscle (Wohlgemuth et al., 2010;
McKay et al., 2012; Zhou et al., 2013). In contrast, many investi-
gators have failed to demonstrate age-related enhancement in the
levels of common negative regulators [atrophy gene-1 (atrogin-1),
NF-κB, and calpain] in senescent mammalian muscles (Sakuma
and Yamaguchi, 2011a, 2012c). Currently available data show that
human sarcopenia is attenuated by resistance training, the inges-
tion of amino acids, and treatment with testosterone (Sakuma
and Yamaguchi, 2011a, 2013b; Wakabayashi and Sakuma, 2014).
In addition, myostatin signaling inhibition for mice and calo-
rie restriction for mice and rhesus monkey have been shown to
counteract sarcopenia (Sakuma and Yamaguchi, 2011a, 2013b).
Among this, resistance training in combination with amino acid-
containing nutrition is the best candidate to attenuate age-related
muscle wasting and weakness in human.
MUSCULAR DYSTROPHY
The neuromuscular disorders are a heterogeneous group of
genetic diseases, causing progressive loss of motor ability. More
than 30 genetically defined forms are recognized, and in the
last decade, mutations in several genes that result in the defi-
ciency or loss of function of various important muscle-proteins
have been reported. These include dystrophin, sarcoglycans
(SG), and dysferlin, which are sarcolemmal or peri-sarcolemmal
proteins; α2-laminin and collagen VI, which are extracellular
matrix proteins; and emerin and lamin A/C, which are nuclear
proteins.
Defects in components of the dystrophin–glycoprotein com-
plex (DGC) are known to be an important cause of different
forms of muscular dystrophy (Yoshida and Ozawa, 1990; Ervasti
and Campbell, 1993). The DGC is an oligomeric complex that
connects the subsarcolemmal cytoskeleton to the extracellular
matrix. It consists of dystroglycan (α- and β-DG), SG, and syn-
trophin/dystrobrevin subcomplexes. Mutations in the dystrophin
gene cause the most common form of X-linked Duchenne mus-
cular dystrophy (DMD) (Hoffman et al., 1990). The sarcoglycan
sub-complex is also linked to β-DG and includes α-SG, β-SG,
γ-SG, and δ-SG, which are tightly associated and inserted into
the membrane. Mutations in the genes coding these four SG pro-
teins cause severe forms of limb-girdle muscular dystrophies types
LGMD2D, 2E, 2C, and 2F, respectively. α-DG, a receptor for the
heterodimeric basement membrane protein laminin-2, binds to
β-DG. Mutations in the LAMA2 gene, encoding the α2 chain of
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laminin-2, cause α 2-laminin deficiency and a severe form of con-
genital muscular dystrophy (CMD1A) linked to chromosome 6q
(Helbling-Leclerc et al., 1995). Other milder forms of muscular
dystrophy are caused by mutations in genes coding the enzyme cal-
pain 3 (LGMD2A), the sarcolemmal protein dysferlin (LGMD2B),
and the sarcomeric protein telethonin (LGMD2G) (Vainzof et al.,
2008).
Sarcopenia and muscular dystrophy possess several similar
characteristics as pointed out in more recent review by Rudolf et al.
(2014). Fiber size variability is a major feature of various muscu-
lar dystrophy (Engel and Ozawa, 2004; Taniguchi et al., 2006; Krag
et al., 2011), although it is frequently observed in sarcopenic mam-
malian muscles (Berger and Doherty, 2010; Hepple, 2012). The
occurrence of small fiber groups was reported for samples from
Becker muscular dystrophy (BMD) and DMD (ten Houten and
De Visser, 1984; Engel and Ozawa, 2004), whereas elderly muscle
exhibits extensive fiber type grouping (Kanda and Hashizume,
1989; Andersen, 2003). Rudolf et al. (2014) also indicated co-
expression of multiple myosin heavy chain isoforms in these two
muscles (Marini et al., 1991; Patterson et al., 2006). Furthermore,
both muscles exhibit centralized nuclei, and the accumulation of
fibrosis and intramuscular adipocyte. Although the exact reason
for such a similarity has not been precisely elucidated, it seems
to be feasible to apply same therapeutic approaches to sarcopenia
and muscular dystrophy.
PHOSPHATIDYLINOSITOL-3-KINASE/Akt/MAMMALIAN
TARGET OF RAPAMYCIN
A central pathway involved in hypertrophy is regulated at the
translational level by the serine/threonine kinase Akt. In mus-
cle, Akt is activated by the upstream PI3-K, induced either by
receptor binding or by integrin-mediated activation of focal adhe-
sion kinase (FAK), such as in cardiac myocytes (Sakamoto et al.,
2002). The striking effect of Akt1 on muscle size was demon-
strated by the transient transfection of a constitutively active
inducible Akt1 transgene in skeletal muscle in vivo (Lai et al.,
2004). In addition, muscle mass was completely preserved in
denervated transgenic Akt mice (Pallafacchina et al., 2002). Pos-
sible downstream regulators of Akt, mTOR, and glycogen syn-
thase kinase (GSK)-3β, play a crucial role in the regulation of
translation.
Mammalian target of rapamycin exists in two functionally dis-
tinct multi-protein signaling complexes, mTOR signaling complex
(mTORC)1 and mTORC2. Akt activates mTOR via phosphoryla-
tion and inactivation of tuberous sclerosis complex (TSC)-2. In
general, only signaling by mTORC1 is inhibited by rapamycin,
and thus the growth regulatory effects of rapamycin are believed
to be primarily exerted through the mTORC1 complex (Zoncu
et al., 2011). It is now widely accepted that signaling by mTORC1
is involved in the regulation of several anabolic processes includ-
ing protein synthesis and ribosome biogenesis, as well as catabolic
processes such as autophagy (Zoncu et al., 2011). In skeletal mus-
cle, signaling by mTORC1 has been shown to be regulated by a
variety of different stimuli that control skeletal muscle mass. For
example, signaling by mTORC1 is activated in response to hyper-
trophic stimuli such as increased mechanical loading (mechanical
overloading for the plantaris muscle of mice by surgical ablation),
feeding, and growth factors (Bodine et al., 2001b; Drummond
et al., 2009).
Since signaling through PI3-K/Akt can regulate mTOR-
independent growth regulatory molecules such as GSK-3β, tuberin
(TSC-2), and the forkhead box O (FOXO) transcription factors
(Sandri, 2008), it was not clear whether signaling by mTORC1 is
sufficient, or simply permissive, for the induction of hypertrophy.
For example, Hornberger et al. (2003) found that stretch-induced
activation of mTOR signaling was not abolished in the skeletal
muscle of Akt1−/− mice. Furthermore, Akt-independent stim-
ulation of mTOR may be positively or negatively regulated by
phosphorylation of TSC-2. For instance, TSC-2 is inhibited by
FAK in 293T cells (Gan et al., 2006), suggesting that up-regulation
of FAK expression with increased mechanical loading for skele-
tal muscle could stimulate protein synthesis via TSC-2 inhibition.
All these regulatory influences may explain the rise in the level of
phosphorylated p70S6K (Coffey et al., 2006). Therefore, mTOR
is currently thought to be the major hub for the integration of
an array of upstream signaling pathways that, when activated,
ultimately result in increased translational efficiency (Glass, 2010).
Two of the most studied mTORC1 targets are the eukaryotic
initiation factor 4E binding protein (4E-BP)1 and p70S6K, which
both play important roles in the initiation of mRNA translation.
mTOR phosphorylates and activates the 70-kDa ribosomal pro-
tein S6 kinase (p70S6K), which results in increased translation
either directly or indirectly by activating initiation and elonga-
tion, elongation initiation factor (eIF)-2, eIF4E (through 4E-BP),
and eEF-2 (Glass, 2010). In addition, Akt also phosphorylates and
inactivates GSK-3β, thereby activating translation via the initi-
ation factor eIF2B. Other functions of Akt include the negative
regulation of protein degradation by inhibiting FOXO-mediated
proteasome activity.
Demontis and Perrimon (2009) showed that insulin receptor
signaling and FOXO can regulate skeletal muscle atrophy also in
Drosophila larval muscle. This study shows evolutionarily con-
servation of the mechanisms controlling muscle atrophy. It also
shows a role for the transcription factors Myc and Mnt in this
process (these are new factors that were not known to be involved
in this process in mice or humans). Therefore, it is probable for the
existence of novel signaling pathway via FOXO to regulate muscle
hypertrophy and/or atrophy in mammals.
ADAPTATION OF PI3-K/Akt/mTOR PATHWAY IN AGED MUSCLE
Although many researchers consider PI3-K/Akt/mTOR levels to
decrease with age, studies using sarcopenic muscles from rats
and humans have yielded conflicting results. For example, com-
pared with those in young Fischer 344×Brown Norway rats, the
amounts of phosphorylated mTOR and p70S6K were increased
70–75% in the tibialis anterior (TA) but not in the plantaris mus-
cle of senescent rats (Parkington et al., 2004). Kimball et al. (2004)
showed that, in gastrocnemius muscle, the level of phosphory-
lated p70S6K, eIF2B activity, and the amount of eIF4E associated
with eIF4G increased between 12 and 27 months of age despite
an apparent decrease in Akt activity. In addition, other groups
(Haddad and Adams, 2006; Léger et al., 2008) also showed the
decreased phosphorylation status of Akt in aged mammalian mus-
cle. In contrast, Rahnert et al. (2011) showed only significant
Frontiers in Aging Neuroscience www.frontiersin.org August 2014 | Volume 6 | Article 230 | 3
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Sakuma et al. The regulators of sarcopenia and muscular dystrophy
decrease of phospho-p70S6K (T421/S424) in the aged biceps brachii
and no change in phospho-p70S6K (T389), in spite of significant
age-related decrease in p70S6K in all head and neck, tongue, and
limb muscles (pectoralis, styloglossus, geniohyoid, posterior digas-
tric, and masseter). Therefore, aging did not commonly modulate
the PI3-K/Akt/mTOR-linked molecules in skeletal muscle under
sedentary conditions.
Sarcopenic muscle shows a marked defect in the contraction-
induced activation of these mediators. Parkington et al. (2004)
reported lower levels of phosphorylated p70S6K and mTOR after
high-frequency electrical stimulation [HFES, 3-s trains of pulses
(frequency 100 Hz, duration 1 ms at 10–12 V)] in muscle of senes-
cent rats (30 months of age) compared with those in young rats
(6 months of age). The same roup (Funai et al., 2006) also demon-
strated that 4E-BP1 was markedly phosphorylated in the TA mus-
cle of aged but not young rats at 6 h after HFES. In addition, they
suggested no increase in eIF4E–eIF4G association after HFES in
aged muscle (Funai et al., 2006). Furthermore, Thomson and Gor-
don (2006) suggested impaired overload-induced muscle growth
in old rats possibly due to diminished phosphorylation of mTOR
(Ser2448), p70S6K (mTOR-specific Thr389), rpS6 (Ser235/236), and
4E-BP1. Fry et al. (2011) demonstrated that acute resistance exer-
cise (8 sets of 10 repetitions of leg-extension at 70% 1RM with
3 min of rest between each set) increased muscle-protein syn-
thesis rate, and phosphorylation of mTOR, S6K1, and 4E-BP1
only in younger subjects (27± 2 years old) but not in elderly ones
(70± 2 years old). These lines of evidence clearly show that sar-
copenic muscle exhibits an impairment of Akt/mTOR/p70S6K
signaling after contraction. This defect would explain the limited
capacity for hypertrophy after muscle stimulation in aged animals.
ADAPTATION OF THE PI3-K/Akt/mTOR PATHWAY IN DYSTROPHIC
MUSCLE
Functional deficiency of mTOR-dependent signaling is impli-
cated in muscular dystrophy. Indeed, muscles lacking raptor
(mTORC1 component) but not rictor (mTORC2 component)
become progressively dystrophic and kyphotic, resulting in early
death (Bentzinger et al., 2008). In the soleus and to a lesser extent
in the EDL, raptor-deficient mice exhibited a wide distribution
of fiber size, muscle fibers with centralized nuclei, and structures
reminiscent of central cores (Bentzinger et al., 2008). Dystrophic
muscle seems to exhibit induction of this anabolic pathway. Com-
pared with age-matched wild-type mice, marked increases in
pAkt/Akt, pS6/S6, and p4E-BP1/4E-BP1 were recognized in TA
and diaphragm muscles of 4-month-old mdx mice (De Palma
et al., 2012). Intriguingly, starvation was shown to elicit significant
decreases in these anabolic mediators of mTOR-dependent signal-
ing in both muscles of wild-type mice, but not those of mdx mice.
Such hyperactivation of this signal markedly blocks autophagy-
dependent signaling in both normal and starved mdx mice (De
Palma et al., 2012). Age-related reductions of pAkt and pS6 levels
occur in mdx mouse muscle. Indeed, Mouisel et al. (2010) showed
marked decreases in pAkt (50%) and pS6 (45%) in mdx muscle at
18–24 months old compared with those at 5 months old. Intrigu-
ingly, the stimulation of muscle regeneration by cardiotoxin injury
induces abnormal hyperactivation of pAkt and pS6. Therefore,
sarcopenia muscle of mdx mice exhibits an apparent deficiency
of PI3-K/Akt/mTOR signaling. However, as mdx mice age nor-
mally, caution is required when translating observations from
mdx mice to human DMD patients. In addition, they similarly
observed hyperactivation of pAkt and p4E-BP1, no induction of
LC3-II, and accumulation of p62 in muscles of DMD patients.
At 6 weeks of age, there was a significantly lower level of mTOR
activation in diaphragm muscles of mdx mice compared with that
of age-matched wild-type mice (Eghtesad et al., 2011). mTOR
activation increased with postnatal age in diaphragm muscle of
wild-type mice, but not in mdx mice. In contrast to diaphragm
muscle, mTOR activation was not significantly different in the
TA muscle of mdx and wild-type mice at either 6 or 12 weeks
of age (Eghtesad et al., 2011). As contradicting results relating
to the adaptive changes in PI3-K/Akt/mTOR in muscular dys-
trophy have been observed, future studies using human patients
with muscular dystrophy are required. Strangely, a low-protein
diet (De Palma et al., 2012) and treatment with rapamycin (Eght-
esad et al., 2011) attenuate this anabolic pathway, but Wnt7a (von
Maltzahn et al., 2012) and valproic acid (Gurpur et al., 2009) acti-
vate it. However, such therapeutics with overall different directions
for mTOR-dependent signaling effectively attenuates the muscu-
lar dystrophic phenotype (muscle inflammation such as T-cell
infiltration, fibrosis, myofiber damage, and the decrease of muscle
strength).
SERUM RESPONSE FACTOR
Serum response factor is a ubiquitously expressed member
of the MADS (MCM1, Agamous, Deficiens, and SRF) box
transcription factor family, sharing a highly conserved DNA-
binding/dimerization domain, which binds the core sequence
of SRF/CArG boxes [CC (A/T)6 GG] as homodimers. SRF-
dependent signaling plays a major role in a variety of physiolog-
ical processes, including cell growth, migration, and cytoskeletal
organization (Pipes et al., 2006). Previous results obtained with
specific SRF-knockout models by the Cre–LoxP system empha-
size a crucial role for SRF in postnatal skeletal muscle growth
and regeneration by modulating interleukin-4 and IGF-I (insulin-
like growth factor-I) mRNA expression (Charvet et al., 2006).
More recently, Mokalled et al. (2012) demonstrated that mem-
bers of the myocardin family of transcriptional coactivators,
MASTR, and myocardin-related transcription factor (MRTF)-A,
are up-regulated in satellite cells in response to skeletal muscle
injury. In addition, double-knockout satellite cells (MASTR and
MRTF-A) impair skeletal muscle regeneration, probably due to
the down-regulation of several modulators of cell cycle arrest
(retinoblastoma, etc.). As proposed by Mokalled et al. (2012), the
promoting role on muscle regeneration seems to be attributable
to both MASTR/MEF2 and/or MRTF–A/SRF complexes because
the mouse MASTR protein lacks SRF-interaction regions.
Serum response factor also enhances the hypertrophic process
in muscle fibers after mechanical overloading (Gordon et al., 2001;
Sakuma et al., 2003; Sakuma and Yamaguchi, 2012a, 2013a) as
well as muscle differentiation and MyoD gene expression in vitro
(Gauthier-Rouviére et al., 1996). Although SRF would regulate
proliferation and differentiation using different pathways, it would
mainly activate the differentiation of satellite cells during muscle
hypertrophy. Indeed, we showed that, in mechanically overloaded
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muscles of rats, the SRF protein co-localized with MyoD and
myogenin in myoblast-like cells during the active differentiation
phase (Sakuma et al., 2003). More recently, Guerci et al. (2012)
investigated the functional role of SRF in fiber hypertrophy using
SRFflox/flox:HAS-Cre-ERT2 mice injected with tamoxifen. Guerci
et al. (2012) showed that the selective lack of SRF in myofibers
markedly slows fiber growth after mechanical overloading by mod-
ulating satellite cell proliferation and fusion to the growing fibers.
They demonstrated that, in the overloaded muscle, SRF enhances
the expression of COX2 mRNA, which in turn upregulates IL-4
mRNA and ultimately secretes IL-4 protein. Guerci’s hypothesis
indicated that IL-4 produced by muscle fibers moves into satellite
cells paracrinally to modulate the fusion of satellite cells.
It is proposed that the transcriptional activity of SRF is reg-
ulated by muscle ring finger (MuRF)-2 (Lange et al., 2005) and
striated muscle activators of Rho signaling (STARS) (Kuwahara
et al., 2005). At the M-band, the mechanically modulated kinase
domain of titin interacts with a complex of the protein prod-
ucts of the atrogenes NBR1, p62/SQSTM-1, and MuRFs (Lange
et al., 2005; Puchner et al., 2008). This complex dissociates under
mechanical arrest, and MuRF-1 and MuRF-2 translocate to the
cytoplasm and the nucleus (Lange et al., 2005; Ochala et al., 2011).
One of the probable nuclear targets of MuRFs is SRF (Lange et al.,
2005), suggesting that the MuRF-induced nuclear export and tran-
scriptional repression of SRF may contribute to amplifying the
transcriptional atrophy program (Spencer et al., 2000). Thus, it is
possible that the synergistic transactivation of SRF and SRF-linked
molecules is abrogated by MuRF-2 in vivo. On the other hand, SRF
activity is exquisitely sensitive to the state of actin polymerization.
G-actin monomers inhibit SRF activity, whereas polymerization
of actin occurs in response to serum stimulation and RhoA sig-
naling. In this pathway, signal inputs lower the ratio of globular
actin to fibrillar actin, thereby liberating the binding of MRTF-A
to globular actin, resulting in the nuclear accumulation of MRTF-
A and subsequent SRF-dependent gene expression (Miralles et al.,
2003). It has been well established that overexpression of STARS
contributes to the nuclear translocation of MRTF-A and MRTF-
B (Kuwahara et al., 2005, 2007), and these factors activate SRF
transcription.
ADAPTIVE CHANGES IN SRF-LINKED MOLECULES WITH AGE
Mechanical loading for skeletal muscle is widely accepted to deter-
mine SRF expression. In humans, Lamon et al. (2009) demon-
strated that 8 weeks of resistance training (leg presses, squats,
and leg-extensions) induced increases in SRF mRNA (3-fold) and
nuclear protein (1.25-fold) in the vastus lateralis muscle. In the
same training period, they also observed a similar increase in
the mRNA levels of several SRF-targeted molecules (alpha-actin,
myosin heavy chain IIa, and IGF-I) (Charvet et al., 2006). Using
RT-PCR, crude and fractionated homogenates, and immunoflu-
orescence, our study demonstrated blunted expression of SRF
protein in the quadriceps and triceps brachii muscles in aged mice
(Sakuma et al., 2008). Immunofluorescence microscopy also indi-
cated the selective down-regulation of SRF immunoreactivity in
the cell cytosol but not in Pax7-labeled satellite cells in sarcopenic
mice. In addition, our data showed a decrease in MRTF-A mRNA
(50–70%) and protein (76%) levels in only the nuclear fraction
with age. Furthermore, 60 and 40% decreases in the amount
of STARS mRNA were observed in the quadriceps and triceps
brachii of 24-month-old mice, respectively (Sakuma et al., 2008).
Intriguingly, a decrease of SRF expression achieved by a transgenic
approach using the Cre–LoxP system was found to accelerate the
atrophic process in muscle fibers with age (Lahoute et al., 2008).
These SRF KO mice showed marked deposition of intramuscular
lipids with aging. One morphologic aspect of sarcopenia is the
infiltration of muscle tissue components by lipids because of the
increased frequency of adipocyte or lipid deposition (Dubé and
Goodpaster, 2006) within muscle fibers. As with precursor cells
in bone marrow, liver, and kidney, muscle satellite cells express-
ing the adipocytic phenotype increased with age (Shefer et al.,
2006), although this process is still relatively poorly understood in
terms of its extent and spatial distribution. Lipid deposition, often
referred to as intramuscular lipid deposition, may result from a net
buildup of lipids due to the reduced oxidative capacity of muscle
fibers with aging (Dubé and Goodpaster, 2006). These lines of
evidence clearly show the existence of a defect of SRF signaling in
aged mammalian muscle.
ADAPTIVE CHANGES IN SRF-LINKED MOLECULES WITH MUSCULAR
DYSTROPHY
Serum response factor appears to be linked to the degenerative
process during muscular dystrophy. Significant reductions in the
amount of SRF have been observed (Sakuma et al., 2004), namely,
40–50 and 50–65% at 2 and 12 weeks of age, respectively, in
merosin-deficient congenital muscular dystrophy. Our immuno-
histochemical analysis indicated that mature normal mice had
an abundance of SRF protein in the cytoplasm of several mus-
cle fibers, while the dy mice did not. In the skeletal muscle, there is
no direct evidence of a link between SRF disorders and the patho-
genesis of disease. However, Lange et al. (2005) observed that a
mutation in the TK domain of titin, a possible upstream modula-
tor of SRF,disrupted Nbr1 binding,and led to hereditary myopathy
with early respiratory failure (HMERF). HMERF patient biopsies
revealed diffusible localization of Nbr1, large cytoplasmic aggre-
gates of p62, and the selective accumulation of MuRF-2 in central-
ized nuclei in diseased muscle. Unfortunately, their study did not
examine the localization of SRF in the muscle of HMERF patients.
In contrast, human heart failure was reported to show elevations
of a natural dominant-negative form of SRF arising from alter-
native splicing (Davis et al., 2002). The dominant-negative SRF
isoform potently inhibited SRF-dependent gene expression, mir-
roring the biochemical phenotype seen in SRF-null mice (Davis
et al., 2002). In addition, a subsequent human heart failure study
showed decreases in full-length SRF and elevated expression of a
caspase-3-cleaved product of SRF (Chang et al., 2003). A more
recent review (Miano, 2010) proposed various disorders to be
linked with the SRF mutations as shown by many reliable studies
using cell-specific SRF-knockout phenotypes.
UBIQUITIN–PROTEASOME SYSTEM
The ATP-dependent UPS is essential for regulating protein degra-
dation. The degradation of a protein via the UPS involves two
steps: (1) tagging of the substrate by covalent attachment of
multiple ubiquitin molecules and (2) degradation of the tagged
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protein by the 26S proteasome complex with the release of a
free and reusable ubiquitin. Ubiquitin, composed of 76 amino
acids, is an 8.45-kDa protein that is highly conserved in nearly
all eukaryotes. The ubiquitination of proteins is regulated by at
least three enzymes: ubiquitin-activating enzyme (E1); ubiquitin-
conjugating enzyme (E2); and ubiquitin ligase (E3). Kwak et al.
(2004) suggested that the 14-kDa ubiquitin-conjugating enzyme
E214K and the ubiquitin ligase E3 are particularly important for
the degradation of muscle-proteins. The labeled proteins are then
fed into the cells’ “waste disposers,” the proteasomes, where they
are chopped into small pieces and destroyed.
Atrogin-1 is a member of the Skp1, Cullin 1, and F-box-
containing protein (SCF) complex, which bind together to estab-
lish E3 Ub-protein ligase activity, and features an approximately
40-amino-acid motif known as an F-box. MuRF-1 contains a
canonical N-terminal RING domain characteristic of RING-
containing E3 ligases followed by a MuRF family conserved region,
zinc-finger domain (B-box), and leucine-rich coiled-coil domains.
Consistent increases in atrogin-1 and MuRF-1 gene expression
have been observed in a wide range of in vivo models of skeletal
muscle atrophy including diabetes, cancer, renal failure, dener-
vation, unweighting, and glucocorticoid or cytokine treatment
(Bodine et al., 2001a; Lecker et al., 2004). The importance of these
atrophy-regulated genes in muscle wasting was confirmed through
knockout studies in mice where an absence of atrogin-1 or MuRF-
1 attenuated denervation-, fasting-, and dexamethasone-induced
muscle atrophy (Bodine et al., 2001a; Baehr et al., 2011; Cong et al.,
2011).
Yeast two-hybrid analysis identified eIF3 subunit 5 (eIF3-f) and
MyoD as interactors of atrogin-1 (Lagirand-Cantaloube et al.,
2008, 2009). Conversely, the knockdown of atrogin-1 reversed
endogenous MyoD proteolysis and the overexpression of a mutant
MyoD, unable to be ubiquitinated, prevented muscle atrophy
in vivo (Lagirand-Cantaloube et al., 2009). These results confirmed
MyoD as a substrate of atrogin-1, resulting in its polyubiquitina-
tion and subsequent degradation during dexamethasone-induced
myotube atrophy (Jogo et al., 2009). In the heart, atrogin-1 ubiqui-
tinates and reduces the levels of calcineurin A, an important factor
triggering cardiac hypertrophy in response to pressure overload
(Li et al., 2004). Interestingly, immunoprecipitation experiments
in C2C12 myoblasts and myotubes have found that atrogin-1
interacts with sarcomeric proteins, including myosins, desmin,
and vimentin, as well as transcription factors, components of
the translational machinery, enzymes involved in glycolysis and
gluconeogenesis, and mitochondrial proteins (Lokireddy et al.,
2012). Whether atrogin-1 ubiquitinates these proteins has yet to
be proven. In contrast to atrogin-1, it appears that MuRF-1 mainly
interacts with structural proteins. MuRF-1 was reported to interact
with and control the half-life of many important muscle structural
proteins, including troponin I, titin, myosin heavy chain (Clarke
et al., 2007), actin (Polge et al., 2011), myosin binding protein C,
and myosin light chains 1 and 2 (Cohen et al., 2009). For example,
MuRF-1 degrades myosin light chains 1 and 2 under denervation
and fasting conditions (Cohen et al., 2009). These studies sug-
gest that, while numerous stimuli can activate both atrogin-1 and
MuRF-1, the downstream pathways affected may be separate for
each protein.
ADAPTATION OF UPS IN AGED MUSCLE
Only very indirect measurements [small increases in levels of
mRNA encoding some components of the UPS (Bossola et al.,
2008; Combaret et al.,2009) or ubiquitin-conjugate accumulation]
in old muscles of rodents or humans suggested modest activation
of this pathway. Atrogin-1 and/or MuRF-1 mRNA levels in aged
muscle are reportedly increased (Clavel et al., 2006) or unchanged
(Welle et al., 2003; Whitman et al., 2005) in humans and rats, or
decreased in rats (DeRuisseau et al., 2005; Edström et al., 2006).
Even when the mRNA expression of these atrogenes increased
in sarcopenic muscles, this was very limited (1.5- to 2.5-fold)
compared with that in other catabolic conditions (10-fold).
Although various findings have been made regarding the
mRNA levels of both ubiquitin ligases in aged mammalian mus-
cle, the examination of protein levels in sarcopenic muscles did
not support age-related increases in the mRNA of several ubiq-
uitin ligases. For instance, Edström et al. (2006) indicated the
marked up-regulation of phosphorylated Akt and FOXO4 in the
gastrocnemius muscle of aged female rats, probably contribut-
ing to the down-regulation of atrogin-1 and MuRF-1 mRNA.
This result is further supported by the more recent finding of
Léger et al. (2008) who, using human subjects aged 70 years old,
demonstrated decreases in nuclear FOXO1 and FOXO3a by 73
and 50%, respectively, although they did not recognize signifi-
cant age-dependent changes in the expression of atrogin-1 and
MuRF-1 mRNA. The major peptidase activities of the protea-
some (i.e., the chymotrypsin-like, trypsin-like, and caspase-like
activities) were either reduced (as reported in other tissues) or
unchanged with aging (Combaret et al., 2009; Sakuma and Yam-
aguchi, 2011a). In contrast, Altun et al. (2010) recently found
that the hindlimb muscles of (30-month-old) rats contained two
to threefold more 26S proteasomes than purified from muscles
of aged rats, and adult (control) rats showed a similar capacity
to degrade peptides, proteins, and a ubiquitinated substrate, but
differed in the levels of proteasome-associated proteins (e.g., the
deubiquitinating enzyme USP14). Although the activities of many
other deubiquitinating enzymes were greatly enhanced in aged
muscles, levels of polyubiquitinated proteins were higher than
in the adult animals. Interestingly, recent findings indicate that
atrogin-1-knockout mice are short-lived and experience higher
loss of muscle mass during aging than control mice (Sandri et al.,
2013), indicating that the activity of this E3 ubiquitin ligase is
required to preserve muscle mass during aging in mice. Moreover,
MuRF-1-null mice experience higher decay of muscle strength
during aging than controls, although muscle mass is at least in
part preserved in these mice (Hwee et al., 2014). As indicated by
Sandri et al. (2013), chronic inhibition of these atrogenes should
not be considered a therapeutic target to counteract sarcopenia
because this does not prevent muscle loss but instead exacerbates
weakness.
ADAPTATION OF UPS IN MUSCULAR DYSTROPHY
Gene expression profiling in LGMD2A showed overexpression of
UPS-related genes (Keira et al., 2007; Saenz et al., 2008). While
the expression of atrogin-1 and MuRF-1 was not increased in
mouse models of LGMD2A, FOXO1 was strongly up-regulated,
and induced muscle atrophy in calpain-3-deficient mice (Laure
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et al., 2009). More recently, Fanin et al. (2013) demonstrated
that LGMD2A patients exhibit significantly higher expression of
MuRF-1 protein (146± 64% of control) but not atrogin-1 protein
(77± 26% of control) in skeletal muscle.
LGMD2B is due to deficiency of the protein dysferlin, which
causes failure in resealing of the membrane lesions generated
during eccentric muscle contractions (Bansal et al., 2003). Sim-
ilar to LGMD2A, dysferlinopathy patients exhibited more abun-
dant mRNA and protein of MuRF-1 but not atrogin-1 (Fanin
et al., 2014). Activation of UPS in dysferlinopathy has also been
reported in cellular models (patient-derived muscle cells) (Azakir
et al., 2012). Ullrich congenital muscular dystrophy (UCMD) is a
common form of muscular dystrophy associated with defects in
collagen VI. It is characterized by loss of individual muscle fibers
and muscle mass and proliferation of connective and adipose tis-
sues. More recently, Paco et al. (2012) studied muscle biopsies
of UCMD (n= 6), other myopathy (DMD, calpain-3-deficient,
Kearns–Sayre, and nemaline myopathy, n= 12), and control
patients (n= 10) and found reduced expression of atrogin-1 and
MuRF-1 mRNAs in UCMD cases.
In contrast to the case of sarcopenia, pharmacological inhibi-
tion of UPS appears to exert some beneficial effect on muscular
dystrophy. Bonuccelli et al. (2007) indicated that Velcade, once
injected locally into the gastrocnemius muscles of mdx mice,
could upregulate the expression and membrane localization of
dystrophin and members of the DAPC. Gazzerro et al. (2010)
suggested that treatment with Velcade (0.8 mg/Kg) over a 2-week
period reduced muscle degeneration and necrotic features, and
increased muscle size (gastrocnemius and diaphragm), in mdx
muscle fibers. In addition, they observed many myotubes and/or
immature myofibers expressing embryonic myosin heavy chain
in mdx muscle after Velcade administration, probably due to up-
regulation of several myogenic differentiating modulators (MyoD
and Myf-5). They also demonstrated that MG-132 increased
dystrophin, α-sarcoglycan, and β-dystroglycan levels in explants
from BMD patients, whereas it increased levels of the DAPC in
DMD cases.
AUTOPHAGY-DEPENDENT SIGNALING
Macroautophagy (herein autophagy) occurs in all eukaryotic cells
and is evolutionarily conserved from yeast to humans. Autophagy
is a ubiquitous catabolic process that involves the bulk degradation
of cytoplasmic components through a lysosomal pathway (Sandri,
2010, 2011; Neel et al., 2013). This process is characterized by
the engulfment of part of the cytoplasm inside double-membrane
vesicles called autophagosomes. Autophagosomes subsequently
fuse with lysosomes to form autophagolysosomes in which the
cytoplasmic cargo is degraded and the degradation products are
recycled for the synthesis of new molecules. Turnover of most
long-lived proteins, macromolecules, biological membranes, and
whole organelles, including mitochondria, ribosomes, the endo-
plasmic reticulum, and peroxisomes, is mediated by autophagy
(Cuervo, 2004).
At first glance, autophagy was considered a coarse, non-
selective, degradative system, but closer investigation revealed a
different truth. Autophagy represents an extremely refined col-
lector of altered organelles, abnormal protein aggregates, and
pathogens, similar to a selective recycling center rather than a
general landfill (Park and Cuervo, 2013). The selectivity of the
autophagy process is conferred by a growing number of specific
cargo receptors, including p62/SQSTM-1, Nbr1, Nix (Bnip3L),
and optineurin (Shaid et al., 2013). These adaptor proteins are
equipped with both a cargo-binding domain, with the capability
to recognize and attach directly to molecular tags on organelles,
and at the same time an LC3-interacting region domain, able to
recruit and bind essential autophagosome membrane proteins.
De novo formation of autophagosomes is regulated by at least
three molecular complexes: the LC3 conjugation system and the
regulatory complexes governed by unc51-like kinase-1 (ULK1)
and Beclin-1. The conjugation complex is composed of different
proteins encoded by autophagy-related genes (Atg) (Mizushima
and Komatsu, 2011). The Atg12–Atg5–Atg16L1 complex, along
with Atg7, plays an essential role in the conjugation of LC3 to
phosphatidylethanolamine, which is required for the elongation
and closure of the isolation membrane (Mizushima and Komatsu,
2011). This system is under the regulation of at least two major cel-
lular energy-sensing complexes. Under basal conditions, the ULK1
complex is inactivated by phosphorylation through mTORC1,
whereas during autophagy induction mTORC1 is inhibited, thus
enhancing the formation of a complex between ULK1, Atg13,
and FIP200. In addition, mTORC1 can also be negatively regu-
lated independently of Akt by energy stress sensors such as AMPK
and, in a mechanical-activity-dependent manner, through TSC-
1/2. Moreover, AMPK can also directly phosphorylate ULK1 and
Beclin-1 (Kim et al., 2013). During autophagy, the ULK1 complex
is localized to the isolation membrane, where it facilitates the for-
mation of autophagosomes through interaction with the Beclin-1
complex.
Interestingly, that the UPS and the lysosomal–autophagy sys-
tem in skeletal muscle are interconnected was suggested by Mam-
mucari et al. (2007), and Zhao et al. (2007). Both studies identified
FOXO3 as a regulator of the lysosomal and proteasomal path-
ways in muscle wasting. FOXO3 is a transcriptional regulator of
the ubiquitin ligases MuRF-1 and atrogin-1. It has now been
linked to the expression of Atg in skeletal muscle in vivo and
C2C12 myotubes (Zhao et al., 2007). More recently, Masiero et al.
(2009) found an intriguing characteristic using muscle-specific
autophagy-related gene (Atg7) knockout mice. The atrophy, weak-
ness, and mitochondrial abnormalities in these mice are also
features of sarcopenia.
ADAPTATION OF AUTOPHAGY-LINKED SIGNALING IN MUSCLE WITH
AGE
A decline in autophagy during normal aging has been described
for invertebrates and higher organisms (Cuervo et al., 2005). Inef-
ficient autophagy has been attributed a major role in the apparent
age-related accumulation of damaged mitochondria (Terman and
Brunk, 2006).
Demontis and Perrimon (2010) showed that the function of
autophagy/lysosome system of protein degradation declined dur-
ing aging in the skeletal muscle of Drosophila. This results in
the progressive accumulation of polyubiquitin protein aggregates
in senescent Drosophila muscle. Intriguingly, overexpression of
the FOXO increases the expression of many autophagy genes,
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preserves the function of the autophagy pathway, and prevents the
accumulation of polyubiquitin protein aggregates in sarcopenic
Drosophila muscle (Demontis and Perrimon, 2009). Several inves-
tigators reported the autophagic changes in aged mammalian
skeletal muscle (McMullen et al., 2009; Wenz et al., 2009; Wohlge-
muth et al., 2010; Gaugler et al., 2011). Compared with those
in young male Fischer 344 rats, amounts of Beclin-1 were sig-
nificantly increased in the plantaris muscles of senescent rats
(Wohlgemuth et al., 2010). In contrast, aging did not influence
the amounts of Atg7 and Atg9 proteins in rat plantaris mus-
cle (Wohlgemuth et al., 2010). Indeed, Western blot analysis by
Wohlgemuth et al. (2010) clearly showed a marked increase in the
amount of LC3 in muscle during aging. However, they could not
demonstrate an aging-related increase of the ratio of LC3-II to
LC3-I, a better biochemical marker to assess ongoing autophagy.
In contrast, Wenz et al. (2009) recognized a significant increase in
the ratio of LC3-II to LC3-I during aging (3 vs. 22 months) in the
biceps femoris muscle of wild-type mice. None of the studies deter-
mining the transcript level of autophagy-linked molecules found a
significant increase with age (McMullen et al., 2009; Wohlgemuth
et al., 2010; Gaugler et al., 2011). Not all contributors to autophagy
signaling seem to change similarly at both mRNA and protein lev-
els in senescent skeletal muscle. Therefore, sarcopenia may include
a partial defect of autophagy signaling, although more exhaustive
investigation is needed in this field.
Life-long caloric restriction alone, or combined with volun-
tary exercise, resulted in mild reduction of LC3 expression and
lipidation coupled with increased LAMP-2 (lysosomal marker)
expression, suggesting a potential increase in autophagy flux.
No significant age-related increase in autophagy-linked molecules
was observed in MCK-PGC-1α mice. PGC-1α may also enhance
autophagic flux. More recently, GSK-3α was proposed as a critical
regulator of aging in various organs (skeletal muscle, heart, liver,
bone, etc.) via modulating mTORC1 and autophagy. Intriguingly,
mice with null mutation of GSK-3α showed premature death and
acceleration of age-related pathologies such as vacuolar degener-
ation, large tubular aggregates, sarcomere disruption, and striking
sarcopenia in cardiac and skeletal muscle (Zhou et al., 2013). These
GSK-3α KO mice exhibited marked activation of mTORC1 and
associated suppression of several autophagy molecules. Indeed,
unrestrained activation of mTORC1 leads to profound inhibi-
tion of autophagy (Levine and Kroemer, 2008; Kroemer et al.,
2010). Therefore, it is expected that pharmacological inhibition
(everolimus) of mTORC1 rescued the muscular disorder resem-
bling sarcopenia in GSK-3αKO mice (Zhou et al., 2013). Enhance-
ment of autophagy flux (exercise, caloric restriction, etc.) would
be a potential strategy attenuating sarcopenia as well as various
type of muscular dystrophy with autophagy defect (Grumati et al.,
2010; De Palma et al., 2012; Vainshtein et al., 2014).
ADAPTATION OF AUTOPHAGY-LINKED SIGNALING IN MUSCULAR
DYSTROPHY
A finely tuned system for protein degradation and organelle
removal is required for the proper function and contractility of
skeletal muscle (Vainshtein et al., 2014). Inhibition/alteration of
autophagy contributes to myofiber degeneration leading to accu-
mulation of abnormal (dysfunctional) organelles and of unfolded
and aggregation-prone proteins (Masiero et al., 2009; Sandri,
2010), which are typical features of several myopathies (Gru-
mati et al., 2010; Nogalska et al., 2010). Generation of Atg5 and
Atg7 muscle-specific knockout mice confirmed the physiological
importance of the autophagy system in muscle mass maintenance
(Raben et al., 2008; Masiero et al., 2009). The muscle-specific Atg7
knockout mice are characterized by the presence of abnormal
mitochondria, oxidative stress, accumulation of polyubiquitinated
proteins, and consequent sarcomere disorganization (Masiero
et al., 2009). In addition, the central role of the autophagy–
lysosome system in muscle homeostasis is highlighted by lysoso-
mal storage diseases (Pompe disease, Danon disease, and X-linked
myopathy), a group of debilitating muscle disorders characterized
by alterations in lysosomal proteins and autophagosome buildup
(Vainshtein et al., 2014). Intriguingly, all of these myopathies
exhibit the accumulation of autophagic vacuoles inside myofibers
due to defects in their clearance.
Apparent defect of autophagy-dependent signaling is also
observed in various muscular dystrophies. The first evidence of
impaired autophagy in these models was provided by studies in
mice and patients with mutations in collagen VI (Irwin et al.,
2003). Mutations that inactivate Jumpy, a phosphatase that coun-
teracts the activation of VPS34 for autophagosome formation
and reduces autophagy, are associated with centronuclear myopa-
thy (Vergne et al., 2009). De Palma et al. (2012) have described
marked defect of autophagy in dystrophin-deficient mdx mice and
DMD patients. This evidence included the electron microscopic
evaluation of muscle tissue morphology as well as the decreased
expression of autophagic regulator proteins (i.e., LC3-II, Atg12,
Gabarapl1, and Bnip3). In addition, starvation and treatment
with chloroquine, potent inducers of autophagy, did not acti-
vate autophagy-dependent signaling in both TA and diaphragm
muscles of mdx mice (De Palma et al., 2012). Furthermore, mdx
mice and DMD patients exhibited an unnecessary accumulation
of p62 protein, which was lost after prolonged autophagy induc-
tion by a low-protein diet (De Palma et al., 2012). A similar block
in autophagy progression was described in lamin A/C null mice
(Ramos et al., 2012). LGMD2A muscles showed up-regulation of
p62 (2.1-fold) and Bnip3 (3-fold) mRNA and slightly increased
LC3-II/LC3-I protein ratio and p62 (Fanin et al., 2013). Con-
versely, laminin-mutated (dy/dy) animals displayed excessive levels
of autophagy, which is equally detrimental (Carmignac et al.,
2011). These findings suggest that the defect of autophagy sig-
naling has a central role in the degenerative symptoms in various
types of muscular dystrophy. Figure 1 shows a schematic dia-
gram of possible relationship between Akt–mTOR signaling and
autophagy in muscular dystrophy.
MYOSTATIN
Growth and differentiation factor 8, otherwise known as myo-
statin, was first discovered during screening for novel members
of the transforming growth factor-β (TGF-β) superfamily, and
shown to be a potent negative regulator of muscle growth (Lee,
2004). Like other TGF-β family members, myostatin is synthe-
sized as a precursor protein that is cleaved by furin proteases to
generate the active C-terminal dimer. When produced in Chinese
hamster ovary cells, the C-terminal dimer remains bound to the
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FIGURE 1 |The relationship between PI3-K–Akt–mTOR signaling and
autophagy in muscular dystrophy. The major anabolic pathway
regulating protein synthesis in skeletal muscle is mTOR/TORC1 signaling.
Upstream trigger (IGF-1, mechanical stress, etc.) activates mTOR
signaling through a number of different intermediary proteins such as Akt
and Rheb. Several anabolic stimulation increases the amount of activated
Akt, which blocks the nuclear translocation of Foxo3 to enhance the
expression of autophagy-related genes (Bnip, LC3, and Atg12) and
atrogene (atrogin-1 and MuRF-1). In dystrophic muscle, higher Akt
potently blocks the inhibition of Rheb by TSC-1/TSC-2, and hyperactivate
mTORC1. Unnecessary activated mTORC1 would extremely enhance
protein synthesis and blocks autophagy-dependent signaling. Therefore,
muscular dystrophy exhibits apparent defect of autophagic process
similar to sarcopenic muscle.
N-terminal propeptide, which remains in a latent, inactive state
(Wolfman et al., 2003). Most, if not all, of the myostatin protein
that circulates in the blood also appears to exist in an inactive com-
plex with a variety of proteins, including the propeptide. Myostatin
binds to and signals through a combination of ActRIIA/B recep-
tors on the cell membrane, but has higher affinity for activin type
IIB receptor (ActRIIB). On binding to ActRIIB, myostatin forms
a complex with a second surface type I receptor, either activin
receptor-like kinase 4 or 5, to stimulate the phosphorylation of
Receptor Smad (R-Smad) and the Smad2/3 transcription factors in
the cytoplasm. This leads to the assembly of Smad2/3 with Smad4
to form a heterodimer that can translocate to the nucleus and acti-
vate the transcription of target genes (Joulia-Ekaza and Cabello,
2007). Myostatin circulates in the blood in a latent complex with
non-covalently bound propeptide at the N-terminus (Wolfman
et al., 2003).
Studies indicate that myostatin inhibits cell cycle progres-
sion and reduces the levels of myogenic regulatory factors,
thereby controlling myoblastic proliferation and differentiation
during developmental myogenesis (Yang et al., 2007). One of the
known downstream targets of Smad signaling is MyoD. Inter-
estingly, myostatin downregulates MyoD expression in an NF-
κB-independent way (McFarlane et al., 2006). Myostatin also
inhibits Pax3 expression, which is possibly an upstream target of
MyoD (McFarlane et al., 2006). On the other hand, the genetic
loss of myostatin leads to an increase in Akt activity in skeletal
muscle in vivo and in vitro (Morissette et al., 2009). The IGF-
1–Akt–mTOR pathway, which mediates both differentiation in
myoblasts and hypertrophy in myotubes, has been shown to inhibit
myostatin-dependent signaling. Blockade of the Akt–mTOR path-
way using siRNA to RAPTOR, a component of TOR signaling
complex 1 (TORC1), facilitates myostatin’s inhibition of muscle
differentiation because of an increase in Smad2 phosphorylation
(Trendelenburg et al., 2009). Taking these findings, myostatin-
mediated signaling activates FOXO, which leads to the expression
of ubiquitin ligases.
ADAPTIVE CHANGES IN MYOSTATIN IN SARCOPENIC MUSCLE
Myostatin levels increase with muscle atrophy due to unload-
ing in mice and humans (Wehling et al., 2000; Sakuma et al.,
2009), and with severe muscle wasting in patients with cancer
cachexia, chronic heart failure, chronic obstructive pulmonary
disease (COPD), AIDS, and diabetes (Sakuma and Yamaguchi,
2011b). Many researchers have investigated the effect of inhibiting
myostatin to counteract sarcopenia using animals (Siriett et al.,
2006; LeBrasseur et al., 2009; Murphy et al., 2010). LeBrasseur
et al. (2009) reported several positive effects of 4 weeks of treat-
ment with PF-354 (24 mg/Kg) in aged mice. They found that
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PF-354-treated mice exhibited significantly greater muscle mass
(by 12%) probably due to decreased levels of phosphorylated
Smad3 and MuRF-1 in muscle. More recently, Murphy et al. (2010)
showed, by way of once-weekly injections, that a lower dose of PF-
354 (10 mg/Kg) significantly increased the fiber cross-sectional
area (by 12%) and in situ muscle force (by 35%) of aged mice
(21-month-old).
However, the role of myostatin in driving sarcopenia is debated.
There is indeed evidence that myostatin null mice, although they
have a doubling of muscle mass, have reduced specific force and
may be actually prone to sarcopenia, suggesting that the intrinsic
capacity to generate force is perturbed in the absence of myostatin
(Amthor et al., 2007; Gentry et al., 2011). In addition, a recent
study in Drosophila on the myostatin/GDF11 homolog myoglianin
indicates that, in the absence of changes in muscle mass, overex-
pression of myoglianin (Drosophila myostatin) in muscle extends
lifespan and preserves muscle function at least in part by activat-
ing the stress-sensing kinase p38 MAPK, while myoglianin RNAi
in muscle has converse effects (Demontis et al., 2014; Patel and
Demontis, 2014).
In rodent muscle models, studies using sarcopenic muscles
have yielded conflicting results (Haddad and Adams, 2006; Carl-
son et al., 2008; Bowser et al., 2013). Haddad and Adams (2006)
showed lower expression of myostatin mRNA in aged (30-month-
old) than in young (6-month-old) rats. Carlson et al. (2008)
showed higher levels of TGF-β and Smad3 but not myostatin in
sarcopenic muscles of mice. In humans, an early cross-sectional
study of younger, middle-aged, and older men and women sug-
gested that serum myostatin levels increase with advancing age, are
highest in “physically frail” older women, and are inversely associ-
ated with skeletal muscle mass (Yarasheski et al., 2002). However,
several subsequent reports on humans failed to show age-related
differences in either circulating myostatin-immunoreactive pro-
tein or skeletal muscle myostatin mRNA levels (Welle et al., 2003;
Ratkevicius et al., 2011). In contrast, Léger et al. (2008) found
a significant elevation in myostatin mRNA and protein levels by
2- and 1.4-fold in young (20± 0.2 years) males compared with
those in older (70± 0.3 years) ones. These disparate findings sug-
gest that myostatin may not be a primary driver of sarcopenia,
or may instead highlight the complexities related to myostatin
and its measurements. As indicated by a recent review (White
and LeBrasseur, 2014), three possible reasons for this exist. First,
myostatin abundance may not reflect myostatin activity. Indeed,
myostatin is generated as a precursor protein that requires prote-
olytic cleavage first to remove its signal peptide and then to liberate
an N-terminal propeptide and a C-terminal fragment. The mature
biologically active form of myostatin is only a disulfide-linked
dimer of C-terminal fragments. Second, myostatin is further regu-
lated by at least three interacting proteins, namely, GDF-associated
serum protein-1 (GASP-1), follistatin, and follistatin-related gene
(FLRG) (Lee, 2004). It is plausible that the abundance of these
endogenous inhibitors of myostatin and/or the degree to which
they interact with myostatin is independently affected by aging.
Third, we may not detect the expression pattern of myostatin dur-
ing sarcopenia because of very small changes of this molecule at
only a limited position of an organelle (e.g., satellite cells), but
not throughout muscle fibers. Indeed, a recent study revealed that
muscle-derived stem cells from older male patients show a+65%
higher level of myostatin expression than stem cells from younger
patients (McKay et al., 2012). Although myostatin immunoreactiv-
ity on satellite cells gradually decreased the response to acute resis-
tance exercise, old muscles possessed more abundant myostatin
on satellite cells of type II fibers than young muscles postexercise.
More descriptive study to investigate a detailed cellular localization
of myostatin would detect such a limited but important adaptation
of myostatin in sarcopenic muscle.
FUNCTIONAL ROLE OF MYOSTATIN IN DYSTROPHIC MUSCLE
There have been several studies dealing with the adaptive changes
in myostatin expression of muscular dystrophy. Using muscles
from fetopsies, infants (aged 8–10 months), and symptomatic
patients (aged 5–12 years) with DMD, Chen et al. (2005) per-
formed mRNA profiling. They demonstrated no induction of
myostatin mRNA at any stage of the disease determined in their
study. Similarly, no induction of myostatin was also observed
in DMD muscle by Castro-Gago et al. (2006). Zanotti et al.
(2007) showed significant increases in myostatin transcript and
protein levels in DMD myotube cultures in vitro. In contrast,
a screen of 12,488 mRNAs in 16-week-old mouse mdx muscle
showed a marked decrease (fourfold) in myostatin mRNA (Tseng
et al., 2002). Similar down-regulation of myostatin mRNA was
observed in mdx mice using suppression subtractive hybridization
(Tkatchenko et al., 2000). Therefore, myostatin does not seem to
modulate the atrophy and degeneration of skeletal muscle in DMD
and mdx mice, since common adaptation of myostatin levels did
not occur in these dystrophic muscles.
Many mutations in the caveolin-3 gene have been detected
in autosomal dominant LGMD1C and autosomal dominant rip-
pling muscle disease (AD-RMD) (Minetti et al., 1998; Betz et al.,
2001). Immunoprecipitation and subsequent immunoblot analy-
sis revealed that caveolin-3 associates with the type I myostatin
receptor in COS-7 monkey kidney cells in vitro (Ohsawa et al.,
2008). Intriguingly, caveolin-3 seems to suppress myostatin signal-
ing by blocking the type I myostatin receptor. Therefore, caveolin-
3-deficient mice showed hyperphosphorylation of an R-Smad of
myostatin, Smad2, and significant up-regulation of a myostatin
target gene, p21 (Ohsawa et al., 2006). In addition, severe muscle
histopathology was occasionally observed in the proximal mus-
cles of patients with LGMD2I, whereas distal muscles were always
relatively spared. In these patients, the amount of myostatin pro-
tein was highly increased in severely affected muscles compared
with that in mildly affected ones. Hauerslev et al. (2013) hypoth-
esize that alterations in the protein turnover and myostatin levels
could progressively impair the muscle mass maintenance and/or
regeneration, resulting in gradual muscular atrophy in LGMD2I.
However, comprehensive analysis using a larger sample size of
LGMD2I patients is needed as the hypothesis was generated from
a very small sample size (severe phenotype n= 1; mild pheno-
type n= 3). In contrast, our previous study found a marked
increase in mature myostatin protein (26 kDa) in gastrocnemius
and rectus femoris muscles of merosin-deficient congenital dy
mice at 12 weeks of age (Sakuma et al., 2004). In addition, marked
myostatin immunoreactivity was detected in the cytoplasm of
myonuclei and/or satellite cells of dy mice compared with slight
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FIGURE 2 | (A,B)The adaptative changes of positive and negative
regulators for muscle mass in sarcopenia and muscular dystrophy. Both
sarcopenia and muscular dystrophy exhibit the marked defect of
autophagy-dependent signaling possibly the latter due to hyperactivation
of Akt/mTOR/p70S6K pathway. Lower activation of SRF-dependent
signaling has been commonly recognized in these symptoms.
Ubiquitin–proteasome system (Atrogin-1 and MuRF-1) would not regulate
muscle atrophy in the case of sarcopenia. It remains to be elucidated
whether myostatin–Smad pathway regulates to sarcopenic symptom
and/or muscular dystrophy.
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myostatin immunoreactivity at those sites in normal mice. There-
fore, muscular dystrophy except for dystrophin deficiency induces
the enhancement of myostatin-dependent signaling.
Many therapeutic approaches using myostatin attenuation have
been conducted in muscular dystrophy. The use of neutraliz-
ing antibodies to myostatin improved muscle disorders in rodent
models of DMD (mdx) and limb-girdle muscular dystrophy 2f
(Sgcg−/−) (Bogdanovich et al., 2002; Bradley et al., 2008). Tar-
geting of the C-terminal dimer by a neutralizing monoclonal
antibody (JA16) resulted in increases in muscle mass and func-
tion in wild-type mice (Whittemore et al., 2003) and rescued the
pathological phenotype in dystrophin-deficient mdx mice (Bog-
danovich et al., 2002). The latter study was the first to provide
evidence that blocking myostatin in dystrophic mice increased
myofiber size and alleviated the symptoms of the disease, such
as a decline in strength, the degeneration of fibers, and fibro-
sis. The inhibition of myostatin was also effective in alleviat-
ing the pathological phenotype of caveolin-3-deficient mice (a
model of LGMD1C) (Ohsawa et al., 2006). In contrast, myostatin
blockade did not attenuate the pathology in a mouse model of
merosin-deficient muscular dystrophy.
Intriguingly, myostatin inhibition using MYO-029 (Stamu-
lumab) was tested in a prospective, randomized, placebo-
controlled US phase I/II trial in 116 adults with muscular dys-
trophy such as BMD, fascioscapulohumeral muscular dystrophy
(FSHD), and LGMD (Wagner et al., 2008). MYO-029 has good
safety and tolerability except for cutaneous hypersensitivity at
higher doses (10 and 30 mg/Kg),attributed to the need for repeated
protein administration (Wagner et al., 2008). No improvements in
muscle function were noted, but dual-energy radiographic absorp-
tiometry and muscle histological investigations revealed that some
subjects had increased muscle fiber size. The trial study concluded
that the systemic administration of myostatin inhibitors was rela-
tively safe and that more potent inhibitors for stimulating muscle
growth in muscular dystrophy should be considered. However,
careful attention should be paid to myostatin inhibition, as mice
with null mutation of myostatin revealed impaired tendon struc-
ture and function (Mendias et al., 2008). Figures 2A,B provide
an overview of the positive and negative regulator adaptations of
muscle mass in sarcopenia and muscular dystrophy.
CONCLUSION
In conclusion, both sarcopenia and muscular dystrophy exhibit the
marked defect of autophagy-dependent signaling possibly the lat-
ter due to hyperactivation of Akt/mTOR/p70S6K pathway. Lower
activation of SRF-dependent signaling has been commonly recog-
nized in these symptoms. Although studies using rodent muscles
have indicated that Atrogin-1 and MuRF contribute to the protein
degradation in muscular wasting (Bodine et al., 2001a), these atro-
genes do not regulate age-related muscle atrophy. More descrip-
tive study seems to have detected such a limited but important
adaptation of myostatin during sarcopenia.
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